Gülhan GÜLER AVCI

Evaluation of Hematological/Pathological Prognostic Factors and Oncological Outcomes of Patients with Locally Advanced Rectal Cancer Treated with Neoadjuvant Radiotherapy

OBJECTIVEIn this study, we aimed to present our results of overall survival (OS), progression-free survival (PFS)and local control (LC) in approximately five years of follow-up of the patients with locally advancedrectal cancer who underwent neoadjuvant radiotherapy (RT) and to investigate both the pathologicaland hematological parameters that affect the survival.METHODSA total of 76 patients with a pathologic diagnosis of rectum adenocarcinoma and clinical stage I- IVAwho underwent neoadjuvant RT between August 2014 and March 2019 were evaluated retrospectivelyin this study. Eighty-five percent of the patients received 45/50 Gy doses of RT concomitantly with oralcapecitabine. Fifty-eight patients (78.4%) underwent surgery. The median time between the completionof RT and surgery was 65 days.RESULTSThe median follow-up was 25 months. The 2-year OS, PFS and LC rates were 85%, 83.7% and 85.2%, respectively. Positive radial surgical margin was a significant prognostic factor for OS and PFS, but not forLC. The factor affecting OS, PFS and LC was adverse tumor histology (undifferentiated). The prolongationof the time from completion of RT to surgery caused OS and LC to deteriorate. Local control significantlydecreased in patients without concomitant chemotherapy. Among all the hematological parameters (e.g.albumin, WBC, platelet, neutrophil, CA 19-9), only pre RT Hb levels significantly correlated with OS butnot with PFS. CEA’s response to neoadjuvant treatment (NAT) significantly increased OS and PFS.CONCLUSIONAdverse tumor histology, the prolonged time from completion of RT to surgery, CEA’s response to NATand pre RT Hb levels were essential factors that affect survival.

PDF

___

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71−96.
2. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264(11):1444−50.
3. Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, et al. A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002;45(7):857−66.
4. Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89(9):1142−9.
5. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al; German Rectal Cancer Study Group. Preoperative versus postoperative 6 chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731−40.
6. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620−5.
7. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355(11):1114−23.
8. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv22-iv40.
9. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874−901.
10. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575−82.
11.Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011;29(23):3163−72.
12.Park IJ, You YN, Agarwal A, Skibber JM, RodriguezBigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012;30(15):1770−6.
13.Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11(9):835−44.
14.Fokas E, Ströbel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, et al; German Rectal Cancer Study Group. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst 2017;109(12).
15.Blomqvist L, Glimelius B. The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol 2008;47(1):5−8.
16.Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18(3):336−46.
17.Erlandsson J, Lörinc E, Ahlberg M, Pettersson D, Holm T, Glimelius B, et al. Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial. Radiother Oncol 2019;135:178−86.
18.Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34(31):3773−80.
19.Rombouts AJM, Hugen N, Elferink MAG, Nagtegaal ID, de Wilt JHW. Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study. Ann Surg Oncol 2016;23(11):3593−601.
20.Sun Z, Adam MA, Kim J, Shenoi M, Migaly J, Mantyh CR. Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. J Am Coll Surg 2016;222(4):367−74.
21.Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv22-iv40.
22.Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, et al; Dutch Surgical Colorectal Audit. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013;100(7):933−9.
23.Probst CP, Becerra AZ, Aquina CT, Tejani MA, Wexner SD, Garcia-Aguilar J, et al; Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh). Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. J Am Coll Surg 2015;221(2):430−40.
24.Evans J, Bhoday J, Sizer B, Tekkis P, Swift R, Perez R, et al. Results of a prospective randomised control 6 vs 12 trial: is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? Ann Oncol 2016;27(suppl 6):4520.
25.Banwell VC, Phillips HA, Duff MJ, Speake D, McLean C, Williams LJ, et al. Five-year oncological outcomes after selective neoadjuvant radiotherapy for resectable rectal cancer. Acta Oncol 2019;58(9):1267−72.
26.Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373(9666):821−8.
27.Kim MJ, Jeong SY, Park JW, Ryoo SB, Cho SS, Lee KY, et al. Oncologic Outcomes in Patients Who Undergo Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision for Locally Advanced Rectal Cancer: A 14-Year Experience in a Single Institution. Ann Coloproctol 2019;35(2):83−93.
28.Baqar AR, Wilkins S, Staples M, Angus Lee CH, Oliva K, McMurrick P, et al. The role of preoperative CEA in the management of colorectal cancer: A cohort study from two cancer centres. Int J Surg 2019;64:10−5.
29.Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini S, et al. The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiat Oncol 2018;13(1):83.